Background and Purpose: The aim of this study was to determine if circulating levels of pituitary hormones are altered by stroke and, if so, whether these alterations offer insight into specific neurochemical pathways in the region of the central nervous system injury.
I schemic damage to the brain has been shown in animals to alter regional brain catecholamine content.' Catecholaminergic pathways projecting to the hypothalamus, in turn, play an important role in regulating the secretion of hypothalamic releasing hormones. Disruption of catecholaminergic pathways by ischemic brain injury in humans could therefore alter hypothalamic releasing hormone production. This, in turn, could result in disturbance of pituitary hormone secretion. A previous study provided evidence of abnormal neurotransmitter control of growth hormone secretion in men and women with stroke.2 Changes in serum pituitary hormone concentrations resulting from disruption of neurotransmitter pathways within the central nervous system (CNS) might then reflect the extent or location of ischemic brain injury. In this prospective study of 28 postmenopausal women undergoing computed tomographic (CT) studies of the brain for evaluation of clinical evidence of stroke, we sought to determine whether serum levels of several pituitary hormones could be correlated to parameters of brain injury. We chose to examine peripheral concentrations of gonadotropins (luteinizing hormone [LH] and follicle-stimulating hormone [FSH] ) and prolactin as representative of pituitary hormones, the secretion of which is known to be influenced by catecholaminergic pathways, as well as thyrotropin (thyroid-stimulating hormone [ Blood for hormone analyses was drawn between 8 AM and 4 PM by venipuncture. To account for the pulsatile nature of the secretion of gonadotropins, two peripheral blood samples were drawn for gonadotropin determinations, at an interval of 20 minutes or more, from each subject. Gonadotropin assays were performed on these two samples, and the arithmetic mean was used in subsequent calculations. A determination was performed at a single time point for all other hormone analyses. Assays for each of the hormones studied in those with stroke were performed only after all subjects had completed CT scan examination.
Determinations of LH, FSH, prolactin, and TSH concentrations in serum were made in duplicate using radioimmunoassay kits (Diagnostic Products, Los Angeles, Calif.). Estradiol assay was performed with a nonextraction method (Radioassay Systems, Los Angeles, Calif.), triiodothyronine (T3) by a solid-phase component system (Becton Dickinson, Orangeburg, N.Y.), and sex hormone-binding globulin (SHBG) by immunoradiometric methodology (Diagnostic Products). Normal ranges of these hormones for postmenopausal women and assay sensitivity, respectively, are as follows: LH, >21 IU/mL, 2 IU/mL; FSH, >40 IU/mL, 1.2 IU/mL; prolactin, 0-20 ,ug/L, 1.4 ,ug/L; estradiol, 0-14 pg/mL, 8 pg/mL; SHBG, nmol/L, 0.04 nmol/L; T3, 1.53-2.91 nmol/L, 0.075 nmol/L; TSH, 0.5-4.8 mU/L, 0.3 mU/L. Interassay and intraassay coefficients of variation were <13% for all assays.
All data are presented as mean+SEM. Data were analyzed by one-way analysis of variance followed by Tukey's honestly significant difference pairwise comparisons of means or by Kruskal-Wallis nonparametric analysis of variance if variances were significantly different by Bartlett's test. F values are given for comparisons made by one-way analysis of variance. STATISTIX 3.5 software package (Analytical Software, St. Paul, Minn.) was used for these analyses.
Results
Strokes involving, but not necessarily limited to, the following areas were observed by CT imaging. The number in parentheses is the number of individuals with positive findings in the area. An individual may have findings in several areas: right middle cerebral (10); left middle cerebral (4); right posterior cerebral (2); right thalamus (2); left internal capsule (3); basal ganglia excluding the caudate (putamen and globus pallidus) (6); basal ganglia including the caudate (4); white matter (2) . Gonadotropin, Estradiol, Sex Hormone-Binding Globulin Serum LH and FSH concentrations in women with evidence of CNS lesions were stratified by location of the stroke (Table 1 ). The lowest gonadotropin levels were seen in those with stroke including the caudate nucleus (group 3), intermediate levels were found in those with lesions involving the basal ganglia excluding the caudate (group 2), and the highest levels were observed in the group with lesions outside of these two areas (group 1). Mean LH concentration in group 3 was reduced to 15% of that in normal postmenopausal women and 16% of that in group 1 (F=3.69,p<0.02 and p<0.03, respectively). Mean FSH concentration in group 3 was reduced to 25% of that in normal subjects and 24% of that in group 1 (F=5.60, p<0.01 and p<0.01, respectively) ( Severe systemic illness itself is associated with diminished serum gonadotropin levels in both women4-6 and men,5,7 with the lowest values in the most critically ill.6 Because individuals with stroke can be expected to exhibit this endocrine manifestation of general illness, we examined our groups for differences attributable solely to variation in disease severity. Serum T3 levels are a well-known and sensitive correlate of disease severity.8'9 We therefore used serum T3 concentrations as a quantitative measure of degree of illness, having excluded individuals with evidence of intrinsic thyroid disease from study. The mean T3 level in stroke subgroup 2 (basal ganglia infarct excluding the caudate) was less than normal. However, there were no significant differences of T3 concentrations between the three stroke subgroups. Despite the similarity of T3 levels in edly lower in subgroup 3. We therefore conclude that it is the differential effects of the CNS lesions themselves that offer the best explanation for the observed stratification of gonadotropin levels, rather than influences related to disease severity. Longitudinal data help to support this conclusion. In a single case of stroke involving the caudate nucleus so studied, serum LH concentration fell from 67.2 IU/L to 3.7 IU/L and serum FSH concentration fell from 104.9 IU/L to 9.3 IU/L during a 10-day period from acute onset of neurological deficit to follow-up study. During this same period, serum T3 levels rose slightly from 0.95 nmol/L to 1.2 nmol/L, indicative of the lack of relation between alteration of gonadotropin concentration and of underlying biochemical effects attributable to disease severity. Additional studies of this type would add valuable information about the genesis of gonadotropin disruption after stroke.
Serum TSH levels were normal in all stroke subgroups. This finding is consistent with the report by the stroke subgroups, gonadotropin levels were mark-kin-1 a and ,B and tumor necrosis factor-a, when injected intracerebroventricularly, can impair LH secretion in gonadectomized rats. 16 The release of these substances at critical CNS locations after stroke may provide another explanation of our findings.
In conclusion, in a prospective study of postmenopausal women with stroke, we have documented markedly diminished serum gonadotropin levels in those with stroke involving the caudate nucleus. This finding does not appear to be a nonspecific outcome of illness or aging. Although the number of cases studied with caudate involvement was relatively small, the differences noted were of sufficient magnitude to be highly significant. Further confirmation of these findings is required, however. Based on our observations, alterations in gonadotropin secretion could potentially serve as a marker for disturbances in CNS biochemistry after stroke, as well as an indication of location of the lesion.
